AbbVie Inc. reported adjusted earnings per share of $3.65 and net revenues of nearly $17 billion for the second quarter [1], [4].
These results demonstrate the company's ability to maintain growth through its immunology and neuroscience portfolios as it navigates shifting market dynamics. The financial performance signals stability for investors following recent guidance updates.
The company's adjusted earnings per share of $3.65 [1] surpassed the Zacks Consensus Estimate of $3.64 [2]. This figure also exceeds the guidance of $3.57 to $3.61 per share that the company issued earlier in July 2026 [3].
Net revenues reached nearly $17 billion [4], representing a year-over-year growth rate of 10.2% [5]. While a pre-call preview article had estimated revenue at $15 billion [7], the final reported figures reflect a stronger quarterly performance.
Growth was driven largely by the performance of Skyrizi and Rinvoq, which saw a 24% growth rate [8]. These products continue to be central to the company's revenue strategy, supporting the broader expansion of its medical offerings.
Based on these results, AbbVie increased its full-year revenue guidance by $300 million [6]. Liz Shea, the senior vice president of investor relations, said these findings and the updated outlook during a virtual conference call [9].
“Net revenues reached nearly $17 billion”
The increase in full-year guidance and the growth of Skyrizi and Rinvoq suggest that AbbVie is successfully diversifying its revenue streams. By beating both analyst estimates and its own previous guidance, the company is positioning itself to offset the loss of exclusivity on older blockbuster drugs through the aggressive expansion of its newer immunology treatments.
